Boehringer Ingelheim Gives First Dose in Phase 1 Trial of AimedBio-Licensed ADC
The ADC licensed from AimedBio has received its first dose in a Phase 1 clinical trial at Boehringer Ingelheim.
The ADC licensed from AimedBio has received its first dose in a Phase 1 clinical trial at Boehringer Ingelheim.